Disclosure Policy

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.


Clinical Endocrinology Update Steering Committee

The following steering committee members reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

  • Daniel Bessesen, MD has served on the Safety Monitoring Committee for Enteromedics, Inc; and has received grant support from the National Institutes of Health.
  • Sigridur Bjornsdottir, MD, PhD has served on an advisory group for Amgen; has received research support from Shire; and has been a speaker for Mylan and Shire.
  • Marc-Andre Cornier, MD has received grant funding from the National Institutes of Health, the Department of Veterans Affairs, and Regeneron.
  • Monica Gadelha, MD, PhD has served on an advisory board for Novartis; has served as a lecturer for Novartis, Ipsen, and Pfizer; has received an unrestricted research grant from Ipsen; has served as primary investigator of clinical trials for Novartis and Ipsen; and has been employed by Instituto Estadual do Cerebro Paulo Niemeyer.
  • Whitney Goldner, MD has served as primary investigator for Eisai (phase 3 trial) and Roche; and has served as a member of the NCCN thyroid cancer guidelines panel and adrenal tumor/neuroendocrine tumor guidelines panel; and has served on the Trainee and Early Career Development Committee, Awards Committee and Thyroid Cancer Guidelines committee for American Thyroid Association.
  • Tim Korevaar, MD, PhD has received speaker fees from Goodlife Healthcare B.V., Berlin Chemie, and Quidel.
  • Connie Baum Newman, MD has served as a member of the National Lipid Association's Graduate Medical Education Committee and American Heart Association's Clinical Lipidology Committee; has served as the past president of the American Medical Women's Association; and has served on the Food and Drug Administration's Endocrinologic and Metabolic Diseases Advisory Committee.
  • Camille Powe, MD has received salary support and grant funding from the NIH National Institute of Diabetes and Digestives and Kidney Diseases (K23) and the Robert Wood Johnson Foundation's Harold Amos Faculty Development Program; has served as section editor for Current Diabetes Reports; and has participated in the NIH Clinical Research Loan Repayment Program.
  • Micol Rothman, MD has served on the Professional Practice Committee of the American Society for Bone and Mineral Research.

The following faculty report no relevant financial relationships: Richard Bebb, MD; Serena Cardillo, MD


Presenting Faculty

The following presenting faculty reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

  • Bradley Anawalt, MD has served as a consultant to the United States Anti-Doping Agency; has received grant funding from the NIH; has served as a Senior Editor for Clinical Endocrinology; and has written chapters in Up-To-Date and Williams, Greenspan and DeGroot's Textbooks of Endocrinology.
  • Melena Bellin, MD has received research support from ViaCyte and Dexom; and has served on the Medical Advisory Board for Ariel Precision Medicine.
  • Anders Carlson, MD has had his institution receive remuneration for consulting and/or clinical research from Novo Nordisk, Sanofi, Medtronic, Dexcom, Abbott, Eli Lilly, and Insulet.
  • Denise Feig, MD, MSc has received speaker fees from Medtronic.
  • Maria Fleseriu, MD has received scientific consulting fees from Novarits and Strongbridge; and has had her institution receive research support from Novartis, Millendo, and Strongbridge
  • Henry N. Ginsberg, MD has received consulting fee from Merck, Amgen, SilenceTherapeutics, Kowa, Pfizer, Janssen, and Resverlogix; and has served as an investigator for Medimmune.
  • George J. Kahaly, MD, PhD has served as a consultant to Quidel USA; and has had his institution receive a research grant from Quidel.
  • Mary-Elizabeth Patti, MD has served as a collaborator for NIH R44 grant funded by Xeris Pharmaceuticals; has worked as a consultant for Fractyl and Eiger Pharmaceuticals; and has received investigator-initiated research support to her institution from Xeris Pharmaceuticals and Dexcom.
  • Donna H. Ryan, MD has received consulting fees from Amgen, Bausch Health, Boeringer Ingelheim, Gila Therapeutics, IFA Celtic, Janssen, KVK Tech, Novo Nordisk, Phenomix, Quintiles, Real Appeal (United Health), ReDesign Health, Sanofi, and Scientific Intake; has served on the speakers bureau for Novo Nordisk; has an ownership interest in Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health and Scientific Intake; and has served on the SELECT Steering Committee for Novo Nordisk.
  • Joy N. Tsai, MD has received research support from Amgen, Inc; and her spouse is employed by Amgen.
  • Joseph G. Verbalis, MD has received consulting fees from Ferring Pharmaceuticals; and has received research support from Corcept Therapeutics.
  • Thomas Weber, MD has served as a consultant to Ultragenyx and Pharacosmos; has received editorial support from Elsevier; has served as a primary investigator for Ultragenyx; has served as an editorial consultant to Med IQ; and has served as a permanent member to the Food and Drug Administration Endocrine and Metabolic Drug Advisory Committee. His spouse has received editorial support from Nivalis Therapeutics; has served as a primary investigator for AstraZeneca; has worked on the Study Section for the NIH National Heart, Lung and Blood Institute; and has served as a permanent member of the Food and Drug Administrations Pulmonary Allergy Drug Advisory Committee.
  • Carol Wysham, MD has served as a consultant to Astra Zeneca, Abbott, Janssen, Novo Nordisk, and Sanaofi; has been in the speakers bureau for Astra Zeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and Sanofi; and has received research funding from Abbott, Novo Nordisk and Mylan.

The following faculty report no relevant financial relationships: Ejigayehu Abate, MD; Shehzad S. Basaria, MD; Alan C. Dalkin, MD; Andrea E. Dunaif, MD; Stephanie Fish, MD; Lauren Fishbein, MD, PhD; Scott Kahan, MD, MPH; Laurence Katznelson, MD; Marie E. McDonnell, MD; Shlomo Melmed, MD; Lynnette K. Nieman, MD; Elizabeth N. Pearce, MD, MSc; Matthew D. Ringel, MD; Robert C. Stanton, MD; Cynthia Stuenkel, MD; Lisa R. Tannock, MD; Margaret E. Wierman, MD; William F. Young, Jr, MD, MSc.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.